{"id":563179,"title":"Policy Statement: Clarifying the appropriate regulatory pathway for subsequent entry low molecular weight heparins - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-02-16","captureTimestamp":"2026-02-16T12:55:24.922000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/policy-statement-clarifying-appropriate-regulatory-molecular-weight-heparins.html","snippet":"Policy Statement: Clarifying the appropriate regulatory pathway for subsequent entry low molecular weight heparins Draft Date: 2013/08/16 1.0 Purpose Health Canada's Biologics and Genetic Therapies Directorate ( BGTD ) is the Canadian federal authority that regulates biological…","rawSnapshotUrl":"/api/snapshots/raw/563179","browseUrl":"https://replay.healtharchive.ca/job-6/20260216125524/https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/policy-statement-clarifying-appropriate-regulatory-molecular-weight-heparins.html#ha_snapshot=563179","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}